Nektar Therapeutics (NKTR)

[SeriousMoney]

NEKTAR UPDATE - 1/27/06
ChangeWave Biotech Investor Alert

The FDA approved Nektar's (NKTR) inhalable insulin product Exubera after the close today and the approval was for both Type I and Type II diabetes in adults.

The product will be marketed by Pfizer (PFE). The press release on the FDA Web site indicated that Exubera would only require a typical FDA Medication Guide (i.e., instructions for use) and is not recommended for people with lung problems and lung diseases -- or for people who have quit smoking in the past six months.

I have taken a lot of flak about Exubera for several years. And there is still debate on Wall Street whether it will be a blockbuster drug. The debate is utter nonsense based on ChangeWave Alliance physician surveys and plain common sense. Would you rather inhale a medication or stick yourself with a needle?

I don't expect a big pop in the stock (mainly due to Wall Street's reaction), but given the power of the Pfizer's sales force you can expect serious sales results within six to nine months -- and good sales results will really put a fire under the stock.